Active Biotech AB

Equities

ACTI

SE0001137985

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 09:10:18 2024-04-25 am EDT			5-day change	1st Jan Change
0.533 ^SEK	-1.66%		-3.09%	+16.76%

Apr. 03	Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops	CI
Feb. 08	Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Active Biotech Announces New Preclinical Data on tasquinimod Will Be Presented at the Annual Meeting of American Society of Hematology

November 04, 2021 at 09:00 am EDT

Active Biotech announced that two abstracts with new preclinical data on tasquinimod, a small molecule immunomodulator, have been accepted for presentation at the 63rd ASH Annual Meeting & Exposition in Atlanta, Georgia, December 11-14, 2021. The results that will be highlighted in the poster presentations are part of Active Biotech?s program to address the unmet medical needs to treat hematological malignances, with focus on multiple myeloma. Currently, a clinical phase Ib/IIa trial in patients with multiple myeloma is ongoing.

Latest news about Active Biotech AB

Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops	Apr. 03	CI
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 08	CI
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
Active Biotech AB Provides Update on the Scheduled Clinical Program for 2024	Dec. 22	CI
Active Biotech Raises SEK44 Million via Rights Offering	Dec. 06	MT
Active Biotech Teams Up with US Research Group on Clinical Study of Laquinimod Eye Drops	Dec. 06	MT
Active Biotech AB Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee	Dec. 01	CI
Active Biotech Plans SEK51 Million Rights Issue; Shares Sink	Nov. 09	MT
Active Biotech AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Active Biotech AB Announces Two Abstracts with Preclinical Data for Tasquinimod in Myelofibrosis and Myelodysplastic Syndrome Have Been Accepted for Presentation At Ash 2023	Nov. 02	CI
Active Biotech AB Announces Successful Completion of Dose Escalation of Tasquinimod	23-09-11	CI
Active Biotech AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Active Biotech Signs Collaboration Deal For Blood Cancer Drug Clinical Trial	23-07-31	MT
Active Biotech AB Enters into Clinical Trial Collaboration Agreement for a Clinical Study with Tasquinimod in Myelofibrosis	23-07-31	CI
Active Biotech Announces Positive Interim Data from an Ongoing Study with Tasquinimod in Relapsed and Refractory Multiple Myeloma	23-05-26	CI
Active Biotech AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Active Biotech AB Auditor Raises 'Going Concern' Doubt	23-04-25	CI
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-09	CI
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-09	CI
Active Biotech AB Confirms Positive Clinical Safety Profile of Laquinimod Eye Drops	23-01-30	CI
Active Biotech's Announces Nomination Committee	22-12-05	CI
Active Biotech AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Active Biotech AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI
Active Biotech AB Announces Successful Completion of the First Stage of the Phase Iia Clinical Trial of Naptumomab in Combination with Docetaxel and the Study Is Now Enrolling into the Second Stage	22-06-01	CI
Active Biotech AB announces that Food and Drug Administration has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis	22-05-18	CI

Chart Active Biotech AB

Duration

Period

More charts

Company Profile

Active Biotech AB (publ) is a Sweden-based Company, which develops pharmaceutical products within medical areas where the immune defense is important, including cancer and inflammatory diseases. The project portfolio comprises both small, orally active immunomodulatory molecules and antibody-based immunotherapy.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ACTIVE BIOTECH AB	+16.76%	18M
VERTEX PHARMACEUTICALS INCORPORATED	-1.62%	104B
REGENERON PHARMACEUTICALS, INC.	+3.07%	97.42B
ARGENX SE	+0.96%	22.2B
BIONTECH SE	-16.84%	21.23B
GENMAB A/S	-10.60%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-18.79%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.38%	13.98B
SAREPTA THERAPEUTICS, INC.	+27.43%	11.66B

Bio Therapeutic Drugs